Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs (Q39771144)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q61123608)
(P304) 1190-1202
(P407) (Q1860)
(P433) 8
(P478) 29
(P577) Monday, November 23, 2009
(P921) (Q111140)
(P1433) (Q1568657)
(P1476) "Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs" (language: en)
(P2093) V Ramakrishnan
M Timm
J L Haug
T K Kimlinger
L E Wellik
T E Witzig
S Kumar
A A Adjei
(P2860) (Q34515624)
(Q36395200)
(Q40328451)
(Q40383692)
(Q40399567)
(Q40429629)
(Q36017643)
(Q40459361)
(Q29617585)
(Q40524119)
(Q40490939)
(Q40541706)
(Q40578408)
(Q40683311)
(Q33767810)
(Q34292940)
(Q36356976)
(Q40696931)
(Q40706864)
(Q40720447)
(Q40836610)
(Q40911421)
(Q40972355)
(Q41508787)
(Q53608889)
(Q49286760)
(Q47637765)
(Q42455980)
(Q44265469)
(Q44182944)
(Q43901688)
(Q43830963)
(Q43761443)
(Q40536203)
(Q57785902)
(Q57287719)
(Q72110973)
(Q72084842)
(Q81857804)
(Q74129743)
(Q73572052)
(Q81307807)
(Q74453179)
(Q68643209)
(Q71611794)
other details
description scientific article

External Links